Aniela Montserrat Silva Nolasco | Pharmaceutical Chemistry | Excellence in Research Award

Published on 15/05/202615/05/2026 by Top Pharmaceutical

Excellence in Research Award

Universidad de Castilla-La Mancha, Spain

Aniela Montserrat Silva Nolasco
Affiliation	Universidad de Castilla-La Mancha
Country	Spain
Scopus ID	57221107566
Documents	21
Citations	23
h-index	2
Subject Area	Pharmaceutical Chemistry
Event	International Top Pharmaceutical Awards

Aniela Montserrat Silva Nolasco is a pharmaceutical science researcher associated with Universidad de Castilla-La Mancha, Spain. Her academic profile demonstrates research engagement in molecular pharmacology, pharmaceutical chemistry, cancer biology, and bioactive therapeutic compounds. Published studies associated with her scholarly work examine anticancer properties of argentatins, immunomodulatory activity, and translational therapeutic applications in oncology-related biomedical sciences.[1] Her research contributions are indexed through recognized academic databases including Scopus and ORCID, supporting international visibility and scientific dissemination within pharmaceutical and biomedical research communities.[2]

Contents

Abstract
Keywords
Introduction
Research Profile
Research Contributions
Publications
Research Impact
Award Suitability
Conclusion
External Links
References

Abstract

This article summarizes the academic contributions and pharmaceutical research activities of Aniela Montserrat Silva Nolasco. The profile reflects scholarly involvement in cancer biology, molecular pharmacology, pharmaceutical chemistry, and translational therapeutic research involving argentatin compounds and related bioactive agents.[3] Indexed publications, DOI-linked research outputs, and collaborative scientific studies contribute to the researcher’s academic visibility within pharmaceutical and biomedical sciences.[4]

Keywords

Pharmaceutical Chemistry, Molecular Pharmacology, Anticancer Research, Argentatins, Cancer Biology, Translational Medicine, Immunomodulation, Biomedical Sciences, Oncology Research, Therapeutic Compounds.

Introduction

Pharmaceutical research associated with molecular therapeutics and cancer-related biomedical investigations continues to contribute substantially to contemporary translational medicine. Current scientific developments increasingly emphasize naturally derived compounds with potential therapeutic applications against tumor progression and immune dysregulation.[5] Research contributions associated with Aniela Montserrat Silva Nolasco demonstrate participation in this evolving pharmaceutical research landscape through investigations involving argentatins and cellular pharmacological mechanisms.[6]

Research Profile

The academic profile of Aniela Montserrat Silva Nolasco includes affiliations with Universidad de Castilla-La Mancha and previous research and educational activities associated with pharmaceutical and molecular sciences. Her scholarly background includes pharmaceutical biology, cellular pharmacology, and laboratory-based biomedical investigations relevant to therapeutic development and oncology-focused pharmaceutical sciences.[2]

The Scopus profile linked to the researcher identifies indexed publication activity, citation tracking, and collaborative research participation within pharmaceutical and biomedical disciplines. These indicators support measurable academic visibility and ongoing scholarly communication across internationally indexed scientific platforms.[1]

Research Contributions

Research contributions associated with Aniela Montserrat Silva Nolasco include investigations on argentatin compounds and their biological activity in cancer-related cellular environments. Published studies report antimigratory and antiangiogenic effects alongside analyses of long-term resistance induction associated with argentatin A and argentatin B.[3]

Additional scientific contributions address immunomodulatory activity isolated from guayule-derived compounds and synergistic therapeutic interactions involving 5-fluorouracil in colorectal cancer cell models. These studies contribute to broader translational pharmaceutical research exploring molecular therapeutic strategies in oncology-related biomedical sciences.[4]

Publications

The publication profile associated with Aniela Montserrat Silva Nolasco includes peer-reviewed research outputs indexed through recognized scientific databases. DOI-linked publications contribute to scholarly accessibility, research transparency, and international academic dissemination within pharmaceutical chemistry and molecular biomedical sciences.[3][4]

DOI-linked publications facilitate long-term accessibility and citation reliability within digital academic infrastructures. The use of persistent identifiers further supports research transparency, discoverability, and scholarly preservation across multidisciplinary scientific environments.[3]

Research Impact

Research impact is commonly evaluated using publication visibility, citation performance, indexed dissemination, and scholarly engagement across scientific communities. The researcher’s profile demonstrates documented participation in peer-reviewed pharmaceutical and biomedical research activities through Scopus-indexed publications and DOI-associated scholarly outputs.[1]

The available citation indicators and publication metrics support measurable academic relevance within specialized pharmaceutical chemistry and translational biomedical research domains. Continued scientific dissemination and collaborative publication activity may further strengthen long-term academic visibility and research influence.[2]

Award Suitability

The research activities and scholarly outputs associated with Aniela Montserrat Silva Nolasco align with the objectives of the International Top Pharmaceutical Awards through contributions to pharmaceutical chemistry, cancer-related therapeutic investigations, and molecular biomedical sciences.[6] The profile reflects participation in interdisciplinary scientific studies relevant to pharmaceutical innovation and translational therapeutic development.[3]

Conclusion

Aniela Montserrat Silva Nolasco has contributed to pharmaceutical and biomedical research through studies involving anticancer compounds, immunomodulatory activity, and molecular therapeutic investigations. Her academic profile demonstrates scholarly engagement within pharmaceutical chemistry and translational medicine, supported by indexed publications, collaborative research contributions, and DOI-linked scientific dissemination.[5]

External Links

References

Elsevier. (n.d.). Scopus author details: Aniela Montserrat Silva Nolasco, Author ID 57221107566. Scopus.https://www.scopus.com/authid/detail.uri?authorId=57221107566
ORCID. (2026). Aniela M. Silva-Nolasco ORCID profile, affiliations, and academic activities.https://orcid.org/0000-0002-2134-7551
Silva-Nolasco, A. M., Galvez, B. G., de la Cruz-Morcillo, M. A., & Carmona, M. (2026). Differential anti-cancer effects of argentatin A and B: antimigratory, antiangiogenic, and long-term resistance induction. Industrial Crops and Products.https://doi.org/10.1016/j.indcrop.2026.123255
Silva-Nolasco, A. M., Singh, N., de la Cruz-Morcillo, M. A., García-Martínez, M. M., Zalacain, A., Gálvez, B. G., & Carmona, M. (2024). Immunomodulatory activity of argentatins A and B isolated from guayule. PLOS ONE.https://doi.org/10.1371/journal.pone.0304713
Sánchez‐Olivares, P., Silva‐Nolasco, A. M., de la Cruz‐Morcillo, M. A., García‐Martínez, M. M., Pinedo‐Serrano, A., Carmona, M., & Galán‐Moya, E. M. (2024). Synergistic Potential of Argentatins A and B to Improve 5‐Fluorouracil Cytotoxicity in Colorectal Cancer Cell Models. Journal of Cellular and Molecular Medicine.https://doi.org/10.1111/jcmm.70294

Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Published on 31/07/202504/08/2025 by Top Pharmaceutical

Prof. Dr. Dongshan Zhang | Drug Discovery and Development | Best Researcher Award

Director at nd Xiangya Hospital | Central South University | China

Prof. Dr. Dongshan Zhang is a highly respected Chief Physician and Professor at Central South University, China. A postdoctoral fellow trained in the United States, he is a PhD supervisor and a recipient of China’s National Top Talent Program for Science and Technology Leaders. As Director of both the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair, he leads cutting-edge medical research. With over 46 SCI publications and multiple patents, his work in acute kidney injury has earned him prestigious awards and international acclaim.

Publication Profile

Scopus

Education

Prof. Zhang pursued rigorous academic training in China and completed his postdoctoral fellowship in the United States, gaining advanced insights into nephrology and translational medicine. He earned his medical and doctoral degrees from top Chinese medical universities, where he laid the foundation for his expertise in acute organ injury. His exposure to international research environments shaped his multidisciplinary approach. Now, as a PhD supervisor, he mentors future scientists and clinicians, promoting global research collaborations and innovation in clinical nephrology and emergency medicine.

Experience

Prof. Zhang currently serves as Chief Physician and Professor at Central South University, where he is also a Distinguished Shenghua Scholar Professor. He directs two major research institutes: the Institute of Emergency and Difficult Diseases and the Clinical Medical Research Center for Acute Organ Injury and Repair in Hunan Province. Over his career, he has led four NSFC-funded national research projects and served as Associate Editor for top journals. His commercialized patents and extensive publication record reflect his commitment to translational research and clinical excellence.

Awards

Prof. Zhang’s outstanding contributions have earned him the First Prize of the Natural Science Award of Hunan Province. He has been recognized as a National Top Talent in Science and Technology, awarded for his pioneering work in nephrology and acute organ injury. His research papers have graced the covers of leading journals, affirming his global impact. As a Distinguished Shenghua Scholar Professor and active editorial board member, he continues to shape scientific thought and innovation. His accolades highlight both clinical expertise and trailblazing research excellence.

Research Focus

Prof. Zhang’s primary research centers on Acute Kidney Injury (AKI), encompassing mechanisms of injury, repair, and translational approaches to therapy. His work explores inflammation, apoptosis, and molecular pathways involved in kidney damage. He leads interdisciplinary teams to develop innovative drug targets and biomarkers, bridging basic science and clinical application. With support from multiple NSFC grants, his lab integrates in vivo models, molecular profiling, and AI-driven analytics to advance precision nephrology. His research contributes to improving prognosis and treatment in critical care settings.

Publication Top Notes

Title: PRDM16 acts as a homeostasis regulation factor to suppress the transition of AKI to CKD via upregulation of eukaryotic initiation factor 6
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: PRDM16 suppresses pyroptosis to attenuate the progression of AKI caused by rhabdomyolysis via upregulation of USP10
Journal: Cellular and Molecular Life Sciences
Year: 2025

Title: Mmu_circ_0005698/hsa_circ_0085381/miR-532-3p/Arhgdib axis mediates the ischemic progression of acute kidney injury
Journal: International Immunopharmacology
Year: 2025

Title: Recombinant monoclonal antibody siltartoxatug versus plasma-derived human tetanus immunoglobulin for tetanus: a randomized, double-blind, active-controlled, phase 3 trial
Journal: Nature Medicine
Year: 2025

Title: Inhibition of Mettl3 alleviates low-dose cisplatin-induced renal fibrosis and enhances the chemotherapeutic efficacy in mouse models of cancer
Journal: International Journal of Biological Sciences
Year: 2025

Title: PRDM16 suppresses ferroptosis to protect against sepsis-associated acute kidney injury by targeting the NRF2/GPX4 axis
Journal: Redox Biology
Year: 2024

Title: NRF1-induced mmu_circ_0001388/hsa_circ_0029470 confers ferroptosis resistance in ischemic acute kidney injury via the miR-193b-3p/TCF4/GPX4 axis
Journal: Life Sciences
Year: 2024

Title: Discovery and verification of mmu_Circ_26986/hsa_Circ_0072463 as a potential biomarker and intervention target for sepsis-associated acute kidney injury
Journal: Not specified
Year: Not specified

Conclusion

Prof. Dr. Dongshan Zhang is an outstanding candidate for the Research for Best Researcher Award, possessing an exceptional track record in acute organ injury research, prolific publication output, successful grant leadership, and tangible innovations through patents. His blend of academic excellence, clinical relevance, and translational success makes him a model researcher with substantial contributions to global health and kidney disease research. With minor expansion in global collaborations and strategic outreach, his impact can become even more internationally transformative.

Shobha Singh | Pharmaceutical Chemistry | Pharmaceutical Excellence Award

Published on 17/06/202517/06/2025 by Top Pharmaceutical

Shobha Singh | Pharmaceutical Chemistry | Pharmaceutical Excellence Award

Prof. Dr. Shobha Singh, Hygia Institute of Pharmaceutical Education and Research, Lucknow, India

Prof. Dr. Shobha Singh is a distinguished academic and researcher in pharmaceutical sciences, currently serving at Hygia Institute of Pharmaceutical Sciences, Lucknow 🏫. With a Ph.D. from AcSIR–CSIR-NBRI (2022) and a specialization in Pharmaceutical Chemistry 💊, she brings over a decade of teaching and 6 years of research experience. Her expertise spans synthetic organic chemistry, phytochemistry, and heterocyclic compound synthesis 🔬. A member of IPGA and the Society of Ethnopharmacology 🌱, she has guided numerous M. Pharm. theses and contributed to international conferences. Her passion and innovation continue to drive excellence in drug research and development.

Publication Profile

Orcid

Education

Prof. Dr. Shobha Singh has pursued a strong academic path in the field of pharmaceutical sciences 📚. She earned her Ph.D. from AcSIR, CSIR-NBRI, Lucknow, with a CGPA of 7.42 🧪. She completed her M. Pharm. in Pharmaceutical Chemistry from Uttar Pradesh Technical University in 2008 with an impressive 80.30% 🧬. Her B. Pharm. was accomplished at Northern India Engineering College in 2006 with 65.83% 📖. Prior to that, she excelled in her Intermediate (1999) and High School (1997) from U.P. Board with 70% marks in both 🎯—showcasing a consistent academic record 📈.

Experience

Prof. Dr. Shobha Singh brings over a decade of valuable teaching experience in pharmaceutical sciences 🎓. She began her academic journey as a Lecturer at the Rameshwaram Institute of Technology and Management, Lucknow, from July 23, 2008, to April 2011 🏫. She then served as an Assistant Professor at Sherwood College of Pharmacy, Barabanki, from August 16, 2011, to January 16, 2014 🧪. Currently, she continues to educate and guide M. Pharm. students specializing in Pharmaceutical Chemistry 💊—inspiring future researchers and professionals with her deep subject expertise and mentorship 🌟.

Awards

Prof. Dr. Shobha Singh has marked her journey with notable academic and professional achievements 🏆. She holds a prestigious lifetime membership with the Indian Pharmacy Graduates’ Association (I.P.G.A.) 🧬 and is also a proud member of the Society of Ethnopharmacology 🌿, reflecting her commitment to advancing traditional and modern pharmaceutical sciences. Her academic excellence is further highlighted by qualifying the GATE examination twice, in 2006 and 2009 🎓, and the GPAT examination in 2013 📘. These accolades not only signify her academic rigor but also her dedication to continuous professional growth and research excellence 📈.

Research Focus

Prof. Dr. Shobha Singh’s research focus lies at the intersection of phytochemistry, pharmaceutical chemistry, and natural product pharmacology 🌿🧪. She specializes in the phytochemical investigation and biological evaluation of medicinal plants such as Ajuga parviflora, Sesbania sesban, and Sesbania grandiflora 🌸. Her work spans the synthesis of novel heterocyclic compounds, antioxidant activity, and in silico and in vivo pharmacological screening, particularly for anticonvulsant and anticancer properties 🧬💥. She integrates traditional knowledge with modern techniques like molecular docking, enhancing drug discovery from natural sources 🔍🌍. Her research supports innovation in plant-based drug development.

Publication Top Notes

Phytochemical and pharmacological evaluation of Ajuga parviflora Benth

Synthesis and in silico and in vivo anticonvulsant activities of substituted 2-phenyl indole derivatives

Phytochemical investigation and in-vitro antioxidant activity of Sesbania sesban and Sesbania grandiflora seeds

Rajashree Patnaik | Pharmaceutical Chemistry | Best Researcher Award

Published on 21/05/202521/05/2025 by Top Pharmaceutical

Rajashree Patnaik | Pharmaceutical Chemistry | Best Researcher Award

Dr. Rajashree Patnaik, MBRU, United Arab Emirates

Dr. Rajashree Patnaik is a dedicated biotechnology researcher specializing in inflammation, cancer, and stem cell biology. She earned her Ph.D. in Biotechnology in 2018 from Siksha ‘O’ Anusandhan University, India, with a focus on environmental toxicology using human cord blood stem cells. Currently a Postdoctoral Researcher at MBRU, UAE 🇦🇪, she investigates bioceuticals, statins, and venom-derived peptides in disease models. A Gold Medalist 🎖️ in both BSc and MSc, she has published extensively in international journals and received multiple accolades, including the QUWA Research Award 🏆 and Best Poster Award at an international stem cell conference.

Publication Profile

Google Scholar

Education

Dr. Rajashree Patnaik 🎓 earned her Ph.D. in Biotechnology from Siksha ‘O’ Anusandhan University, Bhubaneswar, in February 2018. Her thesis focused on monitoring the toxicity of environmental chemicals using cultured stem cells from human cord blood 🧪🧫. She is skilled in FACS, cell culture, ELISA, Western Blot, RT-PCR, fluorescence microscopy, and karyotyping 🔬. Dr. Patnaik also holds an MSc in Biotechnology (2009–2011) from Berhampur University, where she studied the impact of climate change on plant productivity 🌱. She completed six months of training at the Institute of Life Sciences, JNU, and has a BSc in Zoology (Hons.).

Awards

Dr. Rajashree Patnaik 🌟 has been honored with the Excellence in Research Award for the Best Research Proposal at the 5th Forum for Women in Research – QUWA, UOS 👩‍🔬. She also received the Best Poster Award at the International Conference on Stem Cells, Cancer & Biotechnology held in Goa, India, in 2016 🧬🏆. Dr. Patnaik is a two-time Gold Medalist, having earned top honors in both her MSc in Biotechnology (2011) and BSc in Zoology (Hons.) from Berhampur University, India 🎖️🎓. Her dedication to science and innovation continues to earn her recognition and inspire excellence.

Research Focus

Dr. Rajashree Patnaik primarily focuses on toxicology, stem cell research, natural product pharmacology, and anti-inflammatory interventions using both traditional and modern scientific methods. Her research spans in vitro cytotoxicity, phytochemical analysis, chemotherapeutic screening, and regenerative medicine, particularly investigating natural compounds like curcumin, oleocanthal, and herbal extracts against microbial pathogens, cancer, and inflammatory diseases. She is also active in exploring NOACs, environmental toxins, and PAR-2-mediated pathways in disease contexts like osteoarthritis and cancer. Her interdisciplinary work integrates cell biology, pharmacognosy, and biomedical applications.

Publication Top Notes

In vitro antibacterial activity, gas chromatography–mass spectrometry analysis of Woodfordia fruticosa Kurz. leaf extract and host toxicity testing with in vitro cultured …

Human dental pulp stem cells differentiation to neural cells, osteocytes and adipocytes-An in vitro study

Reconnoitering the therapeutic role of curcumin in disease prevention and treatment: Lessons learnt and future directions

An in vitro study of Ocimum sanctum as a chemotherapeutic agent on oral cancer cell-line

In vitro combinational efficacy of ceftriaxone and leaf extract of Combretum albidum G. Don against multidrug-resistant Pseudomonas aeruginosa and host-toxicity testing with …

Evaluation of geno-toxicity of methyl parathion and chlorpyrifos to human liver carcinoma cell line (HepG2)

Comparative study on toxicity of methylmercury chloride and methylmercury hydroxide to the human neuroblastoma cell line SH-SY5Y

Beyond anticoagulation: a Comprehensive Review of Non-vitamin K oral anticoagulants (NOACs) in inflammation and protease-activated receptor signaling

Cellular and Nuclear Toxicity of HgCl₂ to In Vitro Grown Lymphocytes from Human Umbilical Cord Blood

Evaluating the potential of Vitamin D and curcumin to alleviate inflammation and mitigate the progression of osteoarthritis through their effects on human chondrocytes: A proof …

Probit analysis of comparative assays on toxicities of lead chloride and lead acetate to in vitro cultured human umbilical cord blood lymphocytes

Akhlesh Kumari | Pharmaceutical Chemistry | Best Researcher Award

Published on 20/05/202520/05/2025 by Top Pharmaceutical

Akhlesh Kumari | Pharmaceutical Chemistry | Best Researcher Award

Mrs. Akhlesh Kumari, IFTM University Moradabad, India

Mrs. Akhlesh Kumari 📚👩‍🎓 is a dedicated academician with 8 years of teaching experience and pursuing Ph.D. in Pharmaceutical Chemistry 📊. With an M. Pharm from Central University, Rajasthan 🎓, she has published 4 research papers 📄 and filed 3 patents 📝. Her research focuses on Pharmaceutical Chemistry 🔬, contributing to the field’s advancement. Mrs. Kumari’s commitment to education and research makes her a promising figure in her field 🌟. With a citation index of 13 📈, she demonstrates her impact on the research community. Her work showcases her potential as a leading researcher 🔍.

Publication Profile

Google Scholar

Education

Mrs. Akhlesh Kumari is a dedicated academician with a strong background in pharmaceutical sciences 📚. With 8 years of teaching experience 📝, she has established herself as a knowledgeable educator. Currently, she is pursuing her Ph.D. from IFTM University, Moradabad, India 🎓, further enhancing her expertise. She holds an M. Pharm degree in Pharmaceutical Chemistry from Central University, Rajasthan, India 🏫. Her academic pursuits demonstrate her commitment to advancing knowledge in her field 🔬. With a passion for teaching and research, Mrs. Kumari is poised to make significant contributions to pharmaceutical sciences.

Professional Memberships

Mrs. Akhlesh Kumari’s professional affiliations are currently focused on her academic and research pursuits 📚. Although she doesn’t hold any specific professional memberships 🤝, her dedication to her field is evident through her teaching and research endeavors. As she continues to grow in her career, potential memberships in professional organizations could further enhance her networking opportunities and contributions to pharmaceutical sciences 🌐. For now, her commitment to education and research remains a priority, driving her to make meaningful impacts in her field 🔬.

Research Focus

Mrs. Akhlesh Kumari focuses her research on organic synthesis, particularly the development of heterocyclic compounds and transition metal-catalyzed reactions such as Ruthenium-catalyzed oxidative annulation. Her work explores the design of novel antimicrobial agents, including thymol-derived chalcones and benzotriazoles, integrating computational studies to understand structure-activity relationships. This research is crucial in the development of new pharmaceutical compounds with potential biological activity. Her studies bridge synthetic organic chemistry and medicinal chemistry, targeting antimicrobial resistance and innovative drug discovery strategies.

Publication Top Notes

Ruthenium‐catalyzed oxidative annulation of anilines using benzothiazole as a removable directing group

Synthesis, computational studies of new thymol derived chalcones and their benzotriazoles as antimicrobial agents

Amedea B. Seabra | Pharmaceutical Chemistry | Excellence in Research

Published on 29/01/202529/01/2025 by Top Pharmaceutical

Amedea B. Seabra | Pharmaceutical Chemistry | Excellence in Research

Assoc. Prof. Dr Amedea B. Seabra, Universidade Federal do ABC, Brazil

Assoc. Prof. Dr. Amedea B. Seabra is a renowned researcher in Chemistry at Universidade Federal do ABC (UFABC), Brazil. With a Ph.D. from UNICAMP, she specializes in biomaterials, nitric oxide release, and drug delivery systems. Her research includes developing novel materials for medical applications, such as nitric oxide-releasing hydrogels and vascular prostheses. Dr. Seabra has contributed significantly to projects related to wound healing and cardiovascular health. She has received numerous accolades, including recognition in global scientific databases and awards for her work on antimicrobial silver nanoparticles. 🌟🔬💉📚🌍

Publication Profile

Google Scholar

Academic Excellence

Assoc. Prof. Dr. Amedea B. Seabra holds a PhD in Chemistry from Universidade Estadual de Campinas (UNICAMP) and completed postdoctoral research at Concordia University and UNICAMP. Specializing in the controlled release of drugs, biomaterials, and nitric oxide chemistry, she has made significant contributions to both basic and applied sciences. Dr. Seabra’s work bridges the gap between research and practical applications, particularly in advancing drug delivery systems and exploring innovative biomaterials. Her research continues to have a profound impact on the development of therapeutic strategies for various medical challenges. 🧪💊🔬🌍

Professional Engagement

Assoc. Prof. Dr. Amedea B. Seabra is a distinguished academic with a wealth of experience in the field of biotechnology. Currently, she serves as the Vice Coordinator at the UFABC Graduate Program in Biotechnology and works as a collaborative researcher at the University of Edinburgh. Dr. Seabra has actively contributed to various international projects, including the prestigious Newton Advanced Fellowship. Her dedication to advancing research and fostering global collaborations highlights her commitment to scientific progress. 🌍🔬👩‍🔬💡

Awards and Recognition

Assoc. Prof. Dr. Amedea has made remarkable contributions to the scientific community, earning widespread recognition for her work. She was included in the prestigious Top 100,000 Scientists by C-Score and named among the most influential scientists globally in 2023 by Elsevier and Stanford University. Her exceptional achievements reflect her dedication and impact in her field. 🌍🔬📚🌟 Her ongoing research continues to inspire and drive advancements, solidifying her place as a leading figure in the scientific world. 👩‍🔬✨

Research Focus

Assoc. Prof. Dr. Amedea B. Seabra’s research focuses on nanotechnology, particularly the toxicology and antimicrobial properties of nanoparticles. Her studies investigate the synthesis, characterization, and biological effects of metal nanoparticles, such as silver and copper, including their cytotoxicity, genotoxicity, and environmental hazards. She has explored the potential of biogenically synthesized nanoparticles and their application in medicine, such as antimicrobial activity and toxicity in model organisms. Her work extends to the use of cellulose nanocrystals in medicine and addresses the risks posed by metal oxide nanoparticles. Overall, her research contributes to the safe application of nanomaterials. 🧬🧪⚛️